Chapter 33: Transplant & Immunosuppressant Drugs

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Welcome back to the Deep Dive.

I hope you have your coffee ready because today we are tackling a topic that is, quite literally,

a matter of life and death.

It really is.

We're cracking open pharmacology,

a patient -centered nursing process approach, specifically the 12th edition.

We are flipping all the way to chapter 33.

Chapter 33.

This is the heavy stuff, transplant drugs.

It really is.

Yeah.

The title sounds simple enough, you know, transplant drugs.

But when you actually start reading, you realize this isn't just about taking a few pills.

Not at all.

This is about managing a biological war inside the human body.

That is exactly what it is.

It's a standoff.

And for the nursing students listening or, you know, the professionals looking for a brush up, this chapter is critical.

Why is that?

Because it completely flips the script on everything you usually learn in pharmacology.

How so?

I mean, usually we're trying to fix something that's broken.

Yeah.

Give a drug to help the body.

Right.

If you have an infection, we give you antibiotics to help your immune system fight it.

If you have cancer, we're trying to boost the body's ability to kill those cells.

But in transplantation, the patient's immune system is functioning perfectly.

It's doing exactly what millions of years of evolution trained it to do.

Which is?

Identify foreign invaders and destroy them.

The problem is that invader is the life -saving heart, kidney, or liver we just surgically implanted.

So the enemy in this whole chapter is actually the patient's own defense system.

Precisely.

And that brings us to the central paradox, or I guess, the mission of this deep dive.

We have to suppress that immune system just enough to stop it from killing the new organ.

But not so much that we leave the patient totally defenseless against the rest of the world.

Exactly.

Not so much that we kill the patient with an infection or, you know, just from the drug's toxicity itself.

It's the ultimate Goldilocks scenario.

Too much drug.

You could die of infection.

Too little drug.

You lose the organ, and you have to find that just right zone, which, by the way, is a moving target every single day.

Wow.

Okay, so before we get into the drugs themselves, and there are a lot to cover, from induction to maintenance, let's just set the stage with the scope of the problem.

Yeah, the numbers are important here.

The text throws some stats at us that are honestly hard to wrap your head around.

They are sobering.

We're talking about end -stage organ failure.

So your heart, your liver, your lungs, your kidneys,

they've failed.

There's often no medication left that can fix it.

Transplantation is the only option.

But the wait list.

The wait list is huge.

Over 100 ,000 people right now.

And that list isn't shrinking.

The text says another person is added every 10 minutes.

Every 10 minutes.

And the really tough statistic, the one that always gets me, is the mortality rate on the list.

Yeah, that one hit me too.

The text says more than 8 ,000 people die every year just waiting.

They never get the call.

Which just highlights why this chapter and these drugs are so important.

When a patient finally gets that organ, whether it's from a cadaver donor or a living donor,

that organ is precious.

It is an incredibly scarce resource.

It is a gift of life.

And the pharmacology we're about to discuss is the only thing standing between that gift and the body's natural impulse to destroy it.

So let's unpack the strategy.

The text makes it very clear.

We don't just use one giant hammer to knock out the immune system.

It's a multi -drug approach.

Correct.

If we use just one drug at a massive, massive dose to stop rejection,

the toxicity would be unbearable.

The kidneys would shut down.

The liver would fail from the drug itself.

So you use a cocktail instead.

We use a cocktail.

Smaller doses of different drugs that attack the immune system from different angles, different mechanisms of action.

It's like a coordinated military strike, right?

You have air support, ground troops, and cyber warfare, all hitting different targets to disable the enemy.

That's a great analogy.

By hitting different targets, we can lower the toxicity of each individual drug while hopefully maximizing the overall suppression of the immune response.

But even with this really smart strategy, the risks are always there.

The text calls them the big three.

The big three.

Rejection, infection, and malignancy.

Malignancy.

As in cancer.

Yes.

Cancer.

You have to remember, your immune system doesn't just fight off bacteria and viruses.

It's also constantly surveying your body for rogue cells that could turn into cancer.

It's called immune surveillance.

And we're shutting that down.

We're dampening it.

Yeah.

So the risk of certain cancers, particularly lymphoma and skin cancer, goes up significantly.

It's a very serious long -term risk.

Wow.

Okay.

Let's get into the weeds then.

The chapter divides this whole journey into phases.

Phase one is induction therapy.

Yeah.

This is right around the time of the surgery, correct?

Yes.

This is the shock and awe phase.

Induction therapy is intense, powerful immunosuppression that's given either right before or immediately after the transplant surgery.

And what's the specific goal here?

Why so intense right at the beginning?

The goal is to immediately diminish antigen presentation and the T cell response.

Think about it.

The surgeon unclamps the blood vessels and for the very first time, the patient's blood rushes into this new kidney or new liver.

The immune system sees it instantly.

Instantly.

And it screams, foreigner,

attack.

So we need to stun the immune system right out of the gate so that acute rejection doesn't happen while the patient is still in the recovery room.

And the key player here, the drug the chapter focuses on for this is called basilixamab.

Basilixamab.

That is a mouthful.

But let's break that name down.

The basimab at the end tells us something, doesn't it?

It does.

AMAB stands for monoclonal

antibodies.

These are antibodies that are created in a lab and they're designed to target one very specific thing.

So they're like sniper rifles, not shotguns.

Perfect analogy.

They are incredibly specific.

And what's the target for basilixamab?

It targets something called the IL -2 receptor, specifically the CD25 subunit, which is on the surface of activated T lymphocyte.

Pretend I'm a first year nursing student again.

Why do I care about the IL -2 receptor?

What is that?

Great question.

So for a T cell, which is like the main soldier of your cell mediated immune system to get activated and start cloning itself to attack the organ, it needs a signal, an order.

Exactly.

That signal is a chemical called interleukin -2 or IL -2.

The IL -2 floats over and it lands on this receptor, kind of like a key going into a lock.

When the key turns, the T cell gets the order to attack.

So what does basilixamab do?

Basilixamab basically puts super in the lock.

It binds to the receptor and blocks it.

So the key, the IL -2 can't get in.

Exactly.

The IL -2 signal is blocked.

The T cell never gets the order to attack.

It's an inhibitor of lymphocyte activation.

It just quiets everything down.

That makes perfect sense.

Now let's talk about the nurse's role here because the administration details are very, very specific in the text.

They are critical.

You can't mess this up.

Basilixamab is given IV.

The first dose is 20 mg and it must be given within two hours before the transplant surgery.

Before.

So the blockade is in place before the patient's blood even touches the new organ for the first time.

Correct.

The defenses are already down.

Then there's a second 20 mg dose that's given four days after the surgery.

But wait, the text has a huge warning here.

A hold criterion for that second dose.

Yes.

And this is a massive clinical judgment point for the nurse.

You do not just blindly give that second dose because it's on the schedule.

You have to assess the situation.

What are you assessing for?

Well, obviously if the patient had a severe hypersensitivity reaction to the first dose, you hold it.

But here's the sadder and more common scenario if the graft is lost.

If the new organ died.

Right.

If the kidney clotted off or if it just failed for some reason in those first four days, you withhold the second dose.

There is no point in continuing to suppress the immune system and risking infection for an organ that isn't viable anymore.

That's a tough The text lists the common ones, abdominal pain, cough, dizziness, tremor.

But then there are some serious adverse reactions that seem, well, they seem paradoxical.

Like sepsis.

Yeah, exactly.

We're giving the drug to save them, but it can cause sepsis, malignancy, and even diabetes.

That is the trade -off we talked about at the beginning.

It's the core dilemma.

But there's one specific reaction that the text puts in a special box, box 33 .1, and that's cytokine

CRS.

This sounds terrifying.

What exactly is happening here?

So when you introduce these powerful monoclonal antibodies, sometimes the immune cells, they're targeting sort of panic before they shut down.

They release a storm of inflammatory chemicals called cytokines into the bloodstream.

A cytokine storm.

We've heard that term before.

Exactly.

And to the nurse at the bedside, this looks scary.

It usually happens within the first hour of the infusion, but it

sounds like they're shaking uncontrollably, tachycardia, so a really fast heart rate, hypotension, where their blood pressure drops,

and dyspnea difficulty breathing.

That sounds exactly like septic shock.

How do you tell the difference?

It mimics it perfectly.

That's why the timing is so important.

If it's happening during the infusion of a drug like this, your first thought should be cytokine release syndrome.

How do we manage it?

Do we just stop the drug and hope for the best?

You absolutely slow or stop the infusion, yes, but the best management is prevention.

That's why you'll almost always see orders for premedication.

Where does that involve?

We give corticosteroids a citaminophen, you know, Tylenol, and an antihistamine like decanhydramine or Benadryl before we even start the Bacilliximab infusion.

We're trying to dampen the body's ability to freak out in the first place.

That's smart.

Okay, before we leave induction therapy, there's a really important warning about pregnancy.

Yes.

Bacilliximab crisis the placenta.

It is not recommended during pregnancy because of the potential risk to the fetus.

The text is very strict here.

What are the guidelines?

Females of childbearing potential need effective contraception before starting treatment, during the entire treatment course, and for four months after the last dose.

Four months after?

That's a long time.

That's the washout period.

It takes that long for to clear the system enough that it's considered safe for a developing baby.

And what about breastfeeding?

The rule is discontinue the drug or discontinue nursing.

You can't do both.

It's a choice between the health of the mother and the health of the infant.

Okay, so that's induction.

The shock and awe is over.

The patient has hopefully survived the surgery.

The organ is working.

Now we move into part two.

The long haul.

Maintenance therapy.

This is the daily grind.

These are the drugs the patient will likely take for the rest of their life or for the life of the transplanted organ.

And the foundation of this maintenance phase seems to be a class of drugs called calcineurin inhibitors or CNIs.

CNIs are the game changers.

I mean, before CNIs came along in the 80s, transplant outcomes were pretty poor.

These drugs truly revolutionized the field.

The prototype drug the chapter discusses is cyclosporine.

Cyclosporine.

It's a fascinating and complicated drug.

So how does it work?

We talked about basilicumab blocking the mailbox on the outside of the cell.

What does cyclosporine do?

Cyclosporine works inside the cell.

It's small enough to get through the cell membrane.

It enters the T lymphocyte and it binds to a protein.

That complex then goes and inhibits an enzyme called calcineurin phosphatase.

Hence the name calcineurin inhibitor.

Right.

And here's why that matters.

Calcineurin is the messenger that runs from the cell surface down to the nucleus to tell the T cell to start making IL -2.

Remember IL -2?

That was the signal to attack.

The key.

Exactly.

So by inhibiting calcineurin, cyclosporine stops the production of IL -2 at the source.

It prevents the factory from even making the keys.

So the T cells simply don't proliferate.

They don't multiply.

You stop the army from recruiting new soldiers.

But this drug comes with baggage.

A lot of baggage.

It absolutely does.

It has a boxed warning for malignancies and serious infections like many of these do.

But the side effect that every nurse needs to be watching for is nephrotoxicity.

Which is so ironic, isn't it?

We're often giving this to kidney transplant patients to save the kidney.

But the drug itself can damage the kidney.

It is the cruel irony of the CNIs.

They cause vasoconstriction in the small blood vessels of the kidneys.

They squeeze them, which can reduce blood flow and damage the delicate kidney structures So monitoring is key.

Monitoring is absolutely non -negotiable.

This is why the text introduces the concept of TDM therapeutic drug monitoring.

Okay, what's that?

We don't just guess the dose.

We have to draw the patient's blood to measure the exact level of the drug in their system.

And the timing of that blood draw is everything.

We draw what's called a trough level.

A trough level.

What does that mean?

It's the lowest level of the drug in the body, which occurs right before the next dose is due.

So if the patient takes their meds at 8 a .m.

every morning, you need to draw their blood at, say, seventh forever or 745 a .m.

What does that number tell you?

It tells you if you're in that Goldilocks zone.

If that trough level is too high, you're risking kidney toxicity.

If it's too low, you're risking rejection.

It's a constant balancing act.

Now there's a very, very famous rule associated with cyclosporine.

I feel like this is the one thing everyone remembers from their pharmacology class.

The grapefruit rule.

The grapefruit rule cannot ignore this.

Yeah, absolutely cannot.

It's a huge patient safety issue.

So why?

What is it about grapefruit specifically?

Why not oranges or apples or bananas?

It all comes down to an enzyme in your gut wall called CYP3A4.

CYP3A4.

Sounds like a robot from Star Wars.

It's basically a metabolic gatekeeper.

When you swallow a pill like cyclosporine, this enzyme in your intestinal wall chews up and breaks down a large chunk of it before it ever reaches your bloodstream.

The dose the doctors prescribe accounts for this breakdown.

They know only a certain percentage is actually going to get through.

Okay, so the system is balanced.

Right.

But grapefruit juice and grapefruit itself contains these compounds called foranocoumarins, and they potently inhibit, they block that CYP3A4 enzyme.

They knock out the gatekeeper.

They knock out the gatekeepers.

So now instead of that controlled, predictable amount of

the drug rushes into the blood.

And you can hit toxic levels.

You can hit toxic levels very, very quickly, just from drinking a glass of grapefruit juice.

And that toxicity, again, means kidney failure.

So the rule is strict.

No grapefruit, no grapefruit juice ever.

Speaking of juice, though,

the text actually recommends using juice to take the medicine.

That seems confusing.

For the oral solution, yes.

The liquid form of cyclosporine doesn't taste great.

The text suggests mixing it with room temperature orange juice or apple juice to make it more palatable.

Okay.

But there's a little nuance here for the perfectionists.

Do not switch diluents frequently.

Why not?

If they're both okay to use, what's the difference?

Because different juices might affect the absorption just a little bit differently.

So if you start with orange juice, stick with orange juice.

If you use apple juice, always use apple juice.

Consistency is key to keeping those blood levels stable.

Got it.

Okay.

So that's cyclosporine.

But the text mentions another CNI that seems to be used even more often now.

Tacrolimus.

Tacrolimus, brand name prograph.

It works the exact same way.

It inhibits calcineurin, but it's more potent.

The book says about 10 to 100 times more potent than cyclosporine.

Wow.

Does that make it better?

It just means you can use a much smaller dose, which is nice.

It's approved for kidney, liver, heart, and lung transplants.

So it's very widely used, but it still carries that same big risk of nephrotoxicity.

You still have to do trough levels.

You still have to watch the kidneys like a hawk.

And does tacrolimus have any unique side effects that are different from cyclosporine?

Yes.

A few big ones.

Neurotoxicity is a major one, headache, tremor, insomnia.

If a patient on tacrolimus comes in and their hands are shaking, one of the first things you do is check their tacro level.

Okay.

What else?

The other big one is metabolic hyperglycemia.

High blood sugar.

Very high blood sugar.

It can actually cause a condition called post -transplant diabetes mellitus.

So we are saving their organ, but we might be giving the patient type 2 diabetes in the process.

It's another one of those difficult trade -offs.

There was also a cardiac warning for tacrolimus mention.

Yes.

Prolonged QT interval.

This refers to the electrical recharging time of the heart between beats.

If that QT interval on the ECG gets too long, it can devolve into a fatal arrhythmia called torsades de pointes.

So what do we monitor for that?

You have to monitor their electrolytes very closely.

Potassium, magnesium, and calcium all play a role.

And you keep an eye on their ECGs.

And just like cyclosporine, does food matter with tacrolimus?

It does.

Food, especially high -fat food, generally reduces the absorption of tacrolimus.

So again, consistency is the name of the game.

If you take it on an empty stomach, always take it on an empty stomach.

If you take it with breakfast, try to always take it with the same kind of breakfast.

Don't vary the routine.

Okay.

Moving on from the CNIs,

let's talk about a drug that works on a totally different signal,

belatacept.

Belatacept.

This is in a class called cost stimulation blockers.

This is a newer approach and it's specifically approved for kidney transplants.

How does it differ from the CNIs?

What's cost stimulation?

Well, remember how we said T cells need a signal to get activated?

It turns out they actually need two signals to really get going.

Signal one is the antigen recognition.

Hey, I see a foreign cell, but that's not enough.

It also needs a second signal, a confirmation signal called cost stimulation.

It's like turning a key and entering a password.

You knew both.

Belatacept blocks that second signal.

So the T cell sees the organ, but it never gets the final go order.

Exactly.

It becomes energetic or unresponsive.

But there is a very specific, very strict rule about who can get this drug.

It involves a virus.

The Epstein -Barr virus or EBV.

This is the virus that famously causes mono or infectious mononucleosis.

Why on earth does a virus I might've had in high school matter for my kidney transplant years later?

Because belatacept has a major black box warning for something called P T L D post -transplant lympho proliferative disorder.

What is that?

It's essentially a type of lymphoma, a cancer of the white blood cells, and it has a nasty habit of showing up in the central nervous system in the brain.

And the risk of this cancer is linked to EBV status.

Yes.

The data shows that patients who are EBV seronegative, meaning they have never been exposed to the virus and have no immunity to it, are at a much, much higher risk of developing this P T L D if they take belatacept.

So before you even think about writing the prescription, you must check their EBV serology.

You have to draw their blood and see if they have antibodies to EBV.

If they are EBV negative, belatacept is contraindicated.

You simply cannot use it.

Period.

That is a critical safety check.

Okay, let's move to the next category.

MTOR inhibitors, serolimus and everolimus.

MTOR stands for mammalian target of rapamycin.

It's another pathway inside the cell.

And these drugs inhibit T lymphocyte activation and also antibody production.

So another way to quiet the immune system.

Right.

The text highlights a very specific limitation for serolimus.

It says safety is not established for liver or lung transplants.

That's a huge red flag.

You need to underline that.

In early studies with liver and lung transplants, serolimus was associated with increased morbidity and mortality.

What happened?

Specifically, there's a risk of

thrombosis.

So blood clots forming in the main artery that feeds the new liver.

That's catastrophic.

So generally you will see this drug used mostly in kidney transplants.

What about side effects when it is used?

Hyperlipidemia is very, very common.

So high cholesterol and high triglycerides.

But the one that surgeons really, really worry about is impaired wound healing.

Why does the surgeon care so much?

Because they just performed a massive surgery.

They sewed an organ in, they closed up layers of muscle and skin.

Serolimus can prevent those tissues from knitting back together properly.

So the wound could just open up?

It can lead to wound adhescence, yes, where the incision splits open.

Or it can cause fluid collections called lymphoceles to form around the new kidney.

So you probably wouldn't want to start this drug immediately after surgery.

Exactly.

Most transplant centers will wait until the surgical wound is well on its way to healing before they'll consider switching a patient to an MTOR inhibitor.

Then we have the purine anti -metabolites.

The chapter lists azathioprine and mycophenolate mofetil.

Let's start with the concept here.

What is an anti -metabolite?

Think of this as cutting off the supply chain for the immune cells.

T cells and B cells, when they get activated, need to divide rapidly.

To divide, they need to replicate their DNA.

And to make DNA, you need building blocks.

You need building blocks called purines.

They're like the bricks for the wall.

Now most cells in your body have a recycling plant, a salvage pathway, that lets them reuse old purines to get these bricks.

But activated T cells and B cells don't.

They're greedy.

They have to make all their purines from scratch.

And these drugs stop that production line.

Exactly.

Both azathioprine and mycophenolate block the synthesis of new purines.

So the T cells and B cells run out of bricks.

They can't build new DNA and they can't divide.

Let's talk about mycophenolate specifically because that seems to be a very common one in the maintenance cocktail.

Mycophenolate mofetil, brand name cellcept.

It's very common, yes, but it has severe black box warning regarding pregnancy.

This is a big one.

What is the risk?

It's associated with an increased risk of first trimester pregnancy loss.

So miscarriage and congenital malformations.

It is teratogenic.

It can severely disrupt fetal development.

So for the nurses handling this drug.

This is a hazardous drug.

You follow hazardous drug precautions.

You do not crush these tablets.

You do not open the capsules.

If you breathe in the powder or get it on your skin, you are exposing yourself to a teratogen.

If you're a nurse who is pregnant or trying to conceive, you need to be extremely careful handling this medication.

And for the female patient taking it.

Strict counseling.

Contraception is mandatory.

Two forms are often recommended.

It's a very serious conversation.

What about side effects for the patient?

Since it stops cell division, I assume it hits other fast -biting cells in the body.

Yes, absolutely.

Specifically the GI tract.

The lining of your gut turns over very rapidly.

So the main complaints are nausea, vomiting, diarrhea, and unfortunately sometimes GI bleeding.

Finally, in the big maintenance cocktail, we have the drug everyone loves to hate.

Corticosteroids like prednisone.

Cute old prednisone.

It's a powerful anti -inflammatory and a very broad immune suppressor.

It works, but the side effect profile is, well, it's a laundry list.

Let's just run through some of them.

It seems to affect almost every single body system.

It does, metabolically.

Hyperglycemia, so high blood sugar, fluid retention leading to edema and weight gain.

Musculoskeletal, it leeches calcium from the bones, causing osteoporosis, and it can cause muscle wasting.

And dermatologic, the skin.

Skin atrophy.

It causes that paper -thin skin that tears and bruises very easily.

And like serolimus, it causes impaired wound healing.

And the famous changes in appearance.

Yes.

The features of Cushing syndrome, the moon face where the face becomes very round, the buffalo hump, which is a fat pad on the back of the neck, and central obesity.

These can be very distressing for patients.

And there's a specific warning for pediatric patients, right?

A huge one.

Growth suppression.

If you give high -dose long -term steroids to a child whose growth plates haven't closed, you can permanently stunt their growth.

It's a major, major concern in pediatric transplant.

So that's the maintenance regimen.

It's this incredible balancing act of all these different drugs.

But even with the best plan, things can go wrong.

Part three of the chapter covers managing complications.

The two cliff on either side of that narrow road.

Rejection and infection.

Let's start with rejection.

If the maintenance drugs aren't enough, or if the patient misses The immune system can wake up and attack.

The text defines three types based on the timeline.

Walk us through them.

First up is hyperacute rejection.

This is the absolute nightmare scenario for a transplant surgeon.

It happens within minutes to hours of the transplant, sometimes right there on the operating table.

Minutes.

How is the body reacting that fast?

It's not T cells doing this, it's pre -existing antibodies.

The patient for some reason already has antibodies in their blood that recognize and attack the donor organ.

How would that happen?

Maybe from a blood transfusion in the past or a previous pregnancy?

Exactly.

Those are the most common ways.

So as soon as the surgeon unclamps the vessels and blood hits the organ, those antibodies swarm it, cause massive clotting, and the organ dies right there.

It turns white, then blue.

Can you fix it?

No.

It is irreversible.

The surgeon has to remove the organ immediately.

It's devastating.

Then there is acute rejection.

This is the most common form of rejection.

It usually happens from a few weeks up to three months post transplant.

This is the classic T cell mediated attack that we've been talking about this whole time.

What are the signs a nurse would see?

Fever, tenderness over the graft site, so the new kidney might be sore, and a spike in the labs.

For a kidney, the creatinine will start to rise.

For a liver, the liver enzymes will go up.

Is this one fixable?

Yes.

This is the key point.

Acute rejection is reversible if you catch it early.

This is where we have to act fast.

We increase the immunosuppression, we might give pulses of high dose steroids, or we might have to bring in the big guns.

And the last type is chronic rejection.

This happens months to years down the road.

It's a slow, insidious decline in organ function.

It's caused by a mix of factors, but it leads to scarring and damage to the blood vessels within the organ.

And unfortunately, it's irreversible.

Okay, let's circle back to that big gun you mentioned for treating acute rejection.

Anti -femicite globulin, or ATG, the source of this drug is unique.

It is.

It's what's called a polyclonal antibody, and it's derived from either rabbits, which gives us thymoglobulin, or horses, which gives us atgam.

The rabbit one is generally more potent and used more often now.

Wait, you're telling me we get this from rabbits and horses?

Yes.

We literally inject human T cells into a rabbit.

The rabbit's immune system recognizes them as foreign and builds a whole army of different antibodies against the human T cells.

We then harvest those rabbit antibodies, purify them, and infuse them into the patient.

So we are injecting rabbit antibodies that are programmed to find and kill human T cells.

Exactly.

It causes profound T lymphocyte depletion.

It basically wipes the chest board clean of T cells.

That sounds incredibly potent, but also incredibly risky.

It is.

I mean, you are effectively removing a huge part of the patient's immune system.

The administration rules are very strict.

It's infused slowly over four to six hours, and you have to watch the patient's blood counts.

They're CBC like a hawk.

The text gives very specific numbers for dose adjustments.

It does.

If the white blood cell count drops to between 2 ,000 and 3 ,000, or if their platelets drop to between 50 ,000 and 75 ,000, you have to cut the next dose in half.

And if they go even lower than that?

If the WBCs are under 2 ,000 or the platelets are under 50 ,000, you stop.

You have to stop treatment.

You cannot leave the patient with absolutely zero defenses.

And I'm guessing just like Bacilliximab, this can cause some serious infusion reactions.

Oh, absolutely.

Maybe even more so.

You are infusing a foreign animal protein directly into the bloodstream.

The body hates it.

Premedication is mandatory.

Steroids, acetaminophen, antihistamines, usually given about one hour prior to the infusion to try and prevent a massive allergic or cytokine response.

So now let's talk about the flip side.

You treat rejection aggressively.

And you create the perfect environment for infection.

The text calls it the Achilles heel of transplantation.

It really is.

Because we suppress the immune system so heavily, patients become vulnerable to opportunistic infections.

These are bugs that wouldn't harm a healthy person, but can be deadly for a transplant recipient.

So the chapter highlights prophylaxis preventative treatment for three specific types.

First, bacterial.

Specifically, something called PJP.

Pneumocystis Girovesi pneumonia.

It used to be called PCP.

It's a fungal -like organism that causes a devastating pneumonia in immunocompromised hosts.

We prevent it with trimethoprim sulfamethoxazole or TMP SMZ, also known as Bactrim or SEPTRA.

And what's the big patient teaching point for that drug?

Sulfa drugs cause photosensitivity.

You have to tell the patient in no uncertain terms.

You must wear sunscreen, SPF 25 or higher, and protective clothing.

If they go out in the sun without protection, they can get a severe blistering sunburn.

Okay.

Second is fungal prophylaxis.

Brush.

All right.

Candida infection in the mouth.

We use Nystatin liquid for this.

And the instruction is swish and swallow.

Explain that technique.

What's the right way to do it?

You don't just drink it like water.

You shake the bottle well, take the dose into your mouth, and then actively swish it around, making sure it coats all the surfaces.

Your tongue, cheeks, gums, roof of your mouth for as long as you can before swallowing it.

Is there anything else?

Yes.

And this is key.

Do not eat or drink for five to 10 minutes afterwards.

You need to let the drug sit on the tissue and do its job.

If you drink water right after, you just wash it all away.

And finally, viral prophylaxis.

CMV.

Is that a megalovirus?

This is a very dangerous virus in transplant patients.

It can directly attack and destroy the new organ, or it can cause things like retinitis, which leads to blindness.

We use antiviral drugs like ganciclover or valganciclover, usually for the first three to six months after transplant.

Okay.

That brings us to part four.

The nurse's role and patient safety.

The drugs don't work if the patient doesn't take them.

And the text drops a really hard truth about adherence.

It does.

It says non -adherence is approximately 50%.

Let that sink in.

Half the patients struggle to take their medications correctly, and it is a top three reason for graft failure.

I just find that so hard to understand.

These patients fought so hard to get the organ.

Why would they stop taking the meds that keep it alive?

It's incredibly complex.

I mean, look at what we just spent the last half hour discussing.

The side effects are brutal.

The nausea, the diarrhea, the tremors, the moon face.

The cost is astronomical.

Thousands of dollars a month.

The pill burden.

Sometimes they're taking 20 pills a day or more.

It's a constant reminder.

It's a constant reminder that you're sick.

And honestly, sometimes they just want to feel normal for a day.

They get tired of it.

It's a huge psychological burden.

The text says we need at least 80 % adherence for the drugs to be effective.

So nurses have to be coaches, not just pill passers.

Absolutely.

Education, motivational interviewing, helping them find pill organizers, connecting them with social work for financial aid.

It's a huge, huge part of the transplant nurse's job.

And part of that education is teaching neutropenic precautions.

This is in Box 33 .2.

This is the how to survive in the world guide for when your white blood cell count is dangerously low.

This is all practical stuff.

Hand hygiene is number one, obviously, avoiding big crowds and sick people.

But let's talk about food safety because that's huge.

No sushi, I'm guessing.

Definitely no sushi.

No raw or undercooked meat.

No runny eggs.

And you have to wash raw fruits and vegetables aggressively.

You need to scrub them to remove any bacteria that might be in the soil.

And pets.

This can be a really tough one for people who love their animals.

But pet waste cat litter boxes, dog feces, even bird cages, is full of pathogens like toxoplasmosis and cryptococcus.

If you absolutely have to be the one to clean it up, you must wear gloves and wash your hands immediately afterwards.

What about gardening?

Soil is teeming with fungi and bacteria.

Aspergillus is a big one.

You have to wear gloves when gardening.

And dental care.

Why does the type of toothbrush matter?

You must use a soft toothbrush.

If you use a hard bristled one and you make your gums bleed, you have just created an open door for all the bacteria that live in your mouth to enter your bloodstream.

In a neutropenic patient, that can lead directly to sepsis.

Okay, let's try to bring this all together with part five of the chapter, the unfolding clinical case study.

This is where we can really put the theory into practice.

Let's meet the patient.

She's a 42 -year -old African -American female.

She has polycystic kidney disease, or PKD, and she's getting a kidney transplant.

Phase I.

Induction.

She's in the hospital.

She gets her basaliximab.

But three days post -op, she develops a fever of 101 .6F, a headache, and nausea.

Okay, so put your nurse hat on.

Day three.

High fever.

What's on your differential?

Is it infection or is it a drug reaction?

The symptoms match cytokine release syndrome.

But that's usually earlier, right?

During the infusion.

Exactly.

A fever on day three makes me worry much more about an infection, a pneumonia, a UTI from the catheter, or a wound infection at the surgical site.

You have to monitor everything.

Culture everything.

Okay.

Phase two.

She's getting ready to go home.

She's on the maintenance cocktail.

Cyclosporine, mycophenolate, prednisone, plus all the prophylaxis meds.

But she voices a concern about the cost.

And that's a red flag for the nurse right there.

That financial stress is a huge risk factor for future non -adherence.

You need to get social work involved before she even leaves the hospital.

Then we get the assessment findings right before discharge.

Her creatinine, which was 1 .7, has now crept up to 2 .0.

Her potassium is high at 5 .3, and she has a low -grade fever.

Stop right there.

That is a siren going off in my head.

A creatinine that is rising, even from 1 .7 to 2 .0, is a sign the kidney isn't filtering well.

Hyperkalemia, the high potassium, confirms that the kidney is struggling.

Add in a fever.

This is acute rejection until proven otherwise.

This patient is not safe to discharge.

So we move to phase three.

The case confirms it is rejection.

The high -dose steroids didn't work.

Now she needs the big gun.

The heavy hitter.

And look at her labs now.

Her absolute neutrophil count, or ANC, is 594.

That is incredibly low.

Normal is over 1500.

She is severely neutropenic.

She has almost no ability to fight off a bacterial infection right now.

The nurse pre -medicates with Tylenol and Benadryl.

But during the ATG infusion, the patient starts to have shakes and chills.

Okay.

So what does that tell us?

It tells us the pre -medication wasn't enough.

She is having an infusion reaction, a cytokine, release in response to those rabid antibodies.

The nurse needs to slow the infusion rate, notify the provider, and probably get an order for some IV steroids.

And one last thing.

She reports that her gums are bleeding when she brushes her teeth.

Which means the neutropenic precautions have failed.

She's probably using a hard toothbrush or being too aggressive.

With an ANC of 594, bleeding gums are not a minor problem.

That's a direct line for oral bacteria to enter her bloodstream.

She is at an extremely high risk for sepsis.

It just really shows how fragile this whole balance is.

One thing goes wrong and it all starts to unravel.

It does.

It requires constant vigilant nursing care.

We are pretty much at the end of our time.

Let's do a quick lightning round just to solidify some of the big takeaways.

Why do we have to use so much caution when combining different immunosuppressants?

Because the risk of infection is additive or even synergistic.

The more drugs you add, the lower the patient's defenses go.

Which virus is critically linked to PTLD and the use of belatacept?

Epstein -Barr virus or EBV.

You always, always have to check the patient's serology status first.

What are some of the main factors influencing patient adherence?

The side effect burden, the financial cost, the sheer number of pills, and the psychological burnout of being a chronic patient.

And finally, a tricky one from the case study review questions.

What do you do if a patient on belatacept becomes pregnant?

You have a long talk about risks and benefits, but generally you continue the drug because losing the transplanted organ is also a major risk to the pregnancy.

And you enroll her in the pregnancy registry to gather more data.

We started this whole deep dive with a paradox.

We did.

And we're ending with one.

We have to injure the immune system to save the body.

The patient has to live their entire life in this tiny precarious gap between rejection on one side and infection on the other.

It's a delicate, difficult place to live.

But thanks to these drugs, and more importantly, thanks to the nurses who manage them and teach the patients how to live there, it's a life that is possible.

Thank you for listening.

This has been the Last Minute Lecture Team.

Thanks everyone.

Stay curious, watch those labs, and we will see you on the next deep dive.